The application of nuclear medicine imaging in neurology, neurosurgery and psychiatry

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 9, 2012, Pages 13-18

  Granov, A M ^a   Tyutin, L A ^a   Stanzhevsky, A A ^a  

^a Russian Center for Research in Radiological and Surgical Technologies   (Russian Federation)

Author keywords

Alzheimer's disease; Amyloid; Anxiety obsessive disorder; Brain tumors; Dementia; Parkinson's disease; PET radiopharmaceutical

Indexed keywords

CENTRAL NERVOUS SYSTEM DISEASE; HUMAN; METHODOLOGY; NEUROLOGY; NEUROSURGERY; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PSYCHIATRY; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTACTIC PROCEDURE; TREATMENT OUTCOME;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; NEUROLOGY; NEUROSURGERY; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRY; STEREOTAXIC TECHNIQUES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 84872349212     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: 10.15690/vramn.v67i9.401     Document Type: Article

References (25)

1. Fago J.P. Dementia: causes, evaluation, and management. Hosp. Pract. (Off Ed). 2001; 36: 59-69.
2. Silverman D.H., Lu CS., Czernin J., Small G.W., Phelps M.E. Prognostic value of brain PET in patients with early dementia symptoms, treated or untreated with anticholinesterase therapy. NucMed. 2000; 41: 64-72.
3. Herholz K. PET studies in dementia. Ann. Nucl. Med. 2003; 17(2): 79-89. (Pubitemid 36693059)
4. Mielke R., Schroder R., Fink G.R., Kessler J., Herholz K., Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol. 1996; 91: 174-179. (Pubitemid 26021405)
5. Imamura T., Ishii K., Sasaki M., Kitagaki H., Yamaji S., Hirono N., Shimomura T., Hashimoto M., Tanimukai S., Kazui H., Mori E. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosti Lett. 1997; 235:49-52. (Pubitemid 27471102)
6. Mielke R., Heiss W.D. Positron emisssion tomography for diagnosis of Alzheimer's disease and vascular dementia. J Neural Transm. 1998; 53: 237-250. (Pubitemid 28361784)
7. 11C]PI B uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain. 2008; 131 (7): 1845-1853.
8. 18F- flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010; 68 (3): 319-29.
9. Dagher A., Owen A.M., Boecker H. The role of the striatum and hippocampus in planning: A PET activation study in Parkinson's disease. Brain. 2001; 124 (5): 1020-1032. (Pubitemid 32458514)
10. Brooks D.J. The early diagnosis of Parkinson's disease. Ann. Neurol. 1998; 44:10-18.
11. Pirker W, Asenbaum S., Hauk M., Kandlhofer S., Tauscher J., Willeit M., Neumeister A., Praschak-Rieder N., Angelberger P., Brucke T. Imaging serotonin and dopamine transporters with 1231-beta-CIT SPECT binding kinetics and effects of normal aging. J. Nucl. Med. 2000; 41 (1): 36-44. (Pubitemid 30046682)
12. Seibyl J.P., Marek K., Sheff K., Zoghbi S., Baldwin R.M., Charney D.S., van Dyck C.H., Innis R.B. Iodine- 123-beta-CIT and iodine123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J. Nucl. Med. 1998; 39 (9): 1500-1508. (Pubitemid 28459875)
13. Leeds N.E., Jackson E.F. Current imaging techniques for the evaluation of brain neoplasms. Curr. Opin. Oncol. 1994; 6: 254-261. (Pubitemid 24146995)
14. Garcia E.V., Faber TL., Galt J.R., Cooke CD., Folks R.D. Advances in nuclear emission PET and SPECT imaging. IEEE Eng. Med. Biol. Mag. 2000; 19: 21-33.
15. Delbeke D., Meyerowitz C, Lapidus R.L., Maciunas R.J., Jennings M.T., Moots P.L., Kessler R.M. Optimal cutoff levels of F-18-fluorodeoxyglucose uptake in the differentiation of lowgrade from high-grade brain tumors with PET. Radiology. 1995; 195: 47-52.
16. Mankoff D.A., Bellon J.R. Positron-emission tomographic imaging of cancer glucose metabolism and beyond. Semin. Radiat. Oncol. 2001;11:16-27. (Pubitemid 32056005)
17. Moulin-Romsee G., D'Hondt E., Groot T., de Goffin J., Sciot R., Mortelmans L., Menten J., Bormans G., van Laere K. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for IIC-methionine? Eur. J. Nucl. Med. Mol. Imaging. 2007; 12: 2082-2087. (Pubitemid 350212139)
18. Bergstrom M. Positron emission tomography in tumor diagnosis and treatment follow-up. Acta Oncol. 1993; 32: 183-188.
19. Benard F., Romsa J., Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin. Nud. Med. 2003; 33:148-162. (Pubitemid 36577057)
20. Ribom D., Eriksson A., Hartman M., Engler H., Nilsson A., Langstrom B. Positron Emission Tomography HC-Methionine and Survival in Patients with Low-Grade Gliomas. Cancer. 2001; 92: 1541-1549. (Pubitemid 32947840)
21. Goldman S., Levivier M., Pirotte B., Brucher J.-M, Wilder D., Damhaut P., Dethy S., Brotchi J., Hildebrand J. Regional Methionine and Glucose Uptake in Highe-Grade Gliomas: A comparative study on PET-Guided Stereotactic Biopsy. J. Nud. Med. 1997; 38:1459-1462. (Pubitemid 27386211)
22. Jager P.L., Vaalburg W, Pruim J., de Vries E.G., Langen K.J., Piers D.A. Radiolabeled Amino Acids: Basic Aspects and Clinical applications in oncology. J. Nucl. Med. 2001; 42:432-445. (Pubitemid 32207394)
23. Langen K.J., Hamacher K., Weckesser M., Floeth F., Stoffels G., Bauer D. O-(2-[18F] fluoroethyl)-L-tyrosine: uptake mechanisms and clinical application. Nucl. Med. Biol. 2006; 33: 287-294.
24. 18 F] FDG PET study in obsessive-compulsive disorder a clinical/metabolic correlation study after treatment. Br. J. Psychiatry. 1995; 166: 244-250.
25. Saxena S., S.L. Rauch Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatric Clinics of North America. 2000; 23: 563-586. (Pubitemid 30666507)